Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Persistent Losses • Equity Dilution RLAY has ample liquidity and low debt, but its minimal revenue, heavy losses, cash burn, dilution, and demanding valuation make it a high-risk investment despite strong balance-sheet resources.
Price Behavior
Key Price Behavior Insights: • Negative momentum • Support holding • Resistance overhead Support Level: $18.38–$18.51 Resistance Level: $19.42–$19.76 RLAY remains cautiously bearish after falling 5.3% last month, with $18.38 support holding but upside limited unless it reclaims $19.42.
Sentiment & News
Key News Insights: • Institutional accumulation • AI drug discovery • CFO share sale Relay Therapeutics saw strong institutional buying and AI-drug-discovery visibility, partly offset by a notable CFO share sale.
AI Summary
RLAY is a well-funded but highly catalyst-dependent oncology bet whose $4.3B valuation hinges on convincing efficacy, safety, and regulatory alignment for its zovegalisib-atirmociclib breast-cancer triplet before Phase 3; investors should prioritize upcoming clinical data and Phase 3 design clarity, as delays or weak results could drive sharp downside and renewed dilution.
Description
Relay Therapeutics is a clinical-stage precision medicines company that uses computational and experimental methods to improve small-molecule discovery, initially concentrating on targeted oncology and genetic disease indications. Its clinical programs include an FGFR2 inhibitor (RLY-4008) in first-in-human testing, a mutant PI3Ka inhibitor program (RLY-2608), and an SHP2 inhibitor (RLY-1971) in Phase 1, and the company maintains research collaborations with D. E. Shaw Research for protein-motion modeling and with Genentech for development and commercialization of RLY-1971. Founded in 2015, Relay Therapeutics is headquartered in Cambridge, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 10 | Apr 17 | RLAY | Relay Therapeutics, Inc. | Relay Therapeutics is an event‑driven biotech with hot‑style catalysts: FDA Breakthrough Therapy designation for zovegalisib + fulvestrant, positive Phase 1b data (median PFS 11.1 months), active Phase 3 (Himalayas‑1) starting in 1H 2026, and additional data slated for spring meetings. The stock is up ~39% in 21 days and ~32% above its 21‑day SMA, giving strong momentum into multiple near‑term data events. | Closed | +12.2% |